B
Bull
Bull · 25%LPTX
$0.44
情境價格
$2.050
+7.556 (+368.57%)收盤時
Loading chart…
- High
- 2.540
- Open
- 0.605
- VWAP
- 1.72
- Vol
- 786.04M
- Mkt Cap
- 67.73M
- Low
- 0.585
- Amount
- 1.36B
- EV/EBITDA, TTM
- 0.00
Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.
Analyst Ratings (2)
Buy
2 Buy
0 Hold
0 Sell
Current: 2.05
最低
—
平均
—
最高
—
HC Wainwright & Co.
Hold
—
2025-03-27
HC Wainwright & Co.
2025-03-27
目標價
—
Hold
HC Wainwright & Co.
Hold
—
2025-01-29
HC Wainwright & Co.
2025-01-29
目標價
—
Hold
HC Wainwright & Co.
Strong Buy
$5.5
2025-01-16
HC Wainwright & Co.
2025-01-16
目標價
$5.5
Strong Buy
HC Wainwright & Co.
Strong Buy
$5.5
2024-11-15
HC Wainwright & Co.
2024-11-15
目標價
$5.5
Strong Buy
HC Wainwright & Co.
Strong Buy
$5.5
2024-08-13
HC Wainwright & Co.
2024-08-13
目標價
$5.5
Strong Buy
估值指標
The current forward P/E ratio for Leap Therapeutics Inc (LPTX) is -0.40, compared to its 5-year average forward P/E of -2.00.
Alphio AI Price Scenarios for LPTX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding LPTX
事件時間軸
資訊
2.011-13TipRanksThree Penny Stocks to Keep an Eye on as of November 13, 2025
- 2.011-13TipRanks
Unpacking the Astonishing Surge in Leap Therapeutics Stock (LPTX)
2.011-12BenzingaCrude Oil Falls 4%; Shares of Holding Companies Surge Following Q3 Earnings Report
4.511-12BenzingaDow Rises Over 400 Points as IHS Holding Reports Positive Q3 Results
9.511-12SeekingAlphaCypherpunk Technologies Reports GAAP EPS of -$0.08
LPTX FAQ — answered by Alphio AI
Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
2 analysts cover LPTX: 2 rate it Buy, 0 Hold and 0 Sell.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。